Business
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
PRESS RELEASE AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm. Maxim Group began covering the stock with a study entitled “Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starti
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE","length":116,"tagName":"p"},{"type":"text","content":"Paris, December 18, 2025, 7.15pm CET","length":36,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm.","length":203,"tagName":"p"},{"type":"text","content":"Maxim Group began covering the stock with a study entitled “Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS”, published on 18 December 2025.","length":172,"tagName":"p"},{"type":"text","content":"In this study, Maxim Group recommended buying the stock, with a target price of €4.00.","length":86,"tagName":"p"},{"type":"text","content":"The study highlights that “Masitinib has generated promising benefits across three neurodegenerative diseases, which we believe validates the mast cell inhibition approach. Considering the underlying efficacy data and safety profile, we view the risk-benefit profile of masitinib as positive. Given the data and opportunity, we initiate coverage with a Buy rating and €4.00 price target. Positive data in progressive MS and in mild AD further supports its neuroprotective potential. We do not model AD or MS and consider them upside”.","length":534,"tagName":"p"},{"type":"text","content":"This initiation completes the coverage of AB Science’s stock and adds to the financial analyst consensus alongside Chardan, In Extenso Finance and DNA Finance.","length":159,"tagName":"p"},{"type":"text","content":"About AB Science","length":16,"tagName":"p"},{"type":"text","content":"Founded in 2001, AB Sci...